CHARGED LIPOSACCHARIDE BASED DRUG DELIVERY SYSTEM

带电脂糖给药系统

• 批准号: DP0558334
• 负责人: Prof Istvan Toth
• 金额: $ 19.42万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0558334
• 关键词: CHARGED; LIPOSACCHARIDE; BASED; DRUG; DELIVERY

Complexation of a drug with lipid and/or sugar units represents one of the most important of the strategies being investigated in this burgeoning field. Increasing the lipid solubility of a hydrophilic compound has been established as an important factor in improving its absorption as it is necessary for passive transport across intestinal mucosal membranes. The role of sugar unit is very important: (i) it modifies the physico-chemical properties (solubility), (ii) utilizes active transport systems (e.g. Glucose transport) and (iii) target the compound - "MAGIC BULET" (Lewis X analogues - damaged cells). There is no limit to the areas of medicine and public health that would benefit from revolutionary new technology in these areas.

药物与脂质和/或糖单元的络合是这一新兴领域正在研究的最重要的策略之一。增加亲水性化合物的脂类溶解度已被确定为改善其吸收的一个重要因素，因为它是被动通过肠粘膜转运所必需的。糖单元的作用非常重要：(I)它改变物理化学性质(溶解度)，(Ii)利用活跃的运输系统(例如葡萄糖转运)，以及(Iii)靶向化合物--“魔球”(Lewis X类似物-受损细胞)。将从这些领域的革命性新技术中受益的医药和公共卫生领域没有限制。